Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 98.95
(-0.3%)
INR 98.95
(-0.3%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.85 Million | -247.13 Million | -172.16 Million | -145.74 Million | -354.97 Million | 38.95 Million |
| Net Income | -197.28 Million | -246.91 Million | -445.26 Million | -283.58 Million | -288.72 Million | -201.22 Million |
| Depreciation & Amortization | 67.66 Million | 65.58 Million | 62.96 Million | 51.23 Million | 46.79 Million | 44.02 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 101.48 Million | -98.38 Million | 158.99 Million | 21.07 Million | -155.75 Million | 137.07 Million |
| Other non-cash items | 95 Million | 32.58 Million | 51.14 Million | 65.52 Million | 42.71 Million | 59.07 Million |
| Investing Cash Flow | -78.16 Million | -126.45 Million | -228.99 Million | -225.49 Million | -102.22 Million | -43.15 Million |
| Investments in PPE | -94.15 Million | -108.7 Million | -235.2 Million | -255.06 Million | -94.11 Million | -46.46 Million |
| Acquisitions | 20.87 Million | 42.87 Million | 35.58 Million | - | - | 5.54 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -4.89 Million | -60.62 Million | -29.37 Million | 29.57 Million | -8.11 Million | -2.24 Million |
| Financing Cash Flow | 102.53 Million | 373.43 Million | 395.05 Million | 376.6 Million | 285.75 Million | 173.2 Million |
| Debt repayment | -102.53 Million | -403.16 Million | -323.83 Million | -334.9 Million | -150.67 Million | -14.34 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 125.13 Million | 104.49 Million | 76.54 Million | 248.22 Million |
| Other Financing Activities | -46.89 Million | 776.59 Million | 593.76 Million | 607.02 Million | 359.88 Million | -60.66 Million |
| Accounts receivables | -13.78 Million | 3.51 Million | -5.76 Million | -977 Thousand | 27.08 Million | -25.86 Million |
| Accounts payables | 36.89 Million | -226.25 Million | 171.29 Million | -18.71 Million | 12.55 Million | 37.02 Million |
| Inventory | 21.49 Million | 136.17 Million | -89.62 Million | -16.04 Million | -60.31 Million | 27.64 Million |
| Other working capital | 56.88 Million | -11.8 Million | 83.08 Million | 56.81 Million | -135.08 Million | 98.26 Million |
| Cash at beginning of period | 859 Thousand | 1 Million | 7.1 Million | 1.74 Million | 173.18 Million | 4.18 Million |
| Cash at end of period | 1.37 Million | 858 Thousand | 1 Million | 7.1 Million | 1.74 Million | 173.18 Million |
| Capital Expenditure | -94.15 Million | -108.7 Million | -235.2 Million | -255.06 Million | -94.11 Million | -46.46 Million |
| Effect of forex changes on cash | - | 1000.00 | - | - | - | 1000.00 |
| Net cash flow / Change in cash | 515 Thousand | -148 Thousand | -6.1 Million | 5.36 Million | -171.44 Million | 169 Million |
| Free Cash Flow | -118 Million | -355.83 Million | -407.36 Million | -400.81 Million | -449.08 Million | -7.51 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -197.28 Million | -49.77 Million | -35.71 Million | -53.32 Million | -246.91 Million | -69.39 Million |
| Depreciation & Amortization | 67.66 Million | 17.3 Million | 17.1 Million | 16.53 Million | 65.58 Million | 14.8 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 101.48 Million | - | - | - | -98.38 Million | - |
| Other non-cash items | 95 Million | -17.3 Million | -17.1 Million | -16.53 Million | 32.58 Million | -14.8 Million |
| Investing Cash Flow | -78.16 Million | - | - | - | -126.45 Million | - |
| Investments in PPE | -94.15 Million | - | - | - | -108.7 Million | - |
| Acquisitions | 20.87 Million | - | - | - | 42.87 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -4.89 Million | - | - | - | -60.62 Million | - |
| Financing Cash Flow | 102.53 Million | - | - | - | 373.43 Million | - |
| Debt repayment | -102.53 Million | - | - | - | -403.16 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | 776.59 Million | - |
| Accounts receivables | -13.78 Million | - | - | - | 3.51 Million | - |
| Accounts payables | 36.89 Million | - | - | - | -226.25 Million | - |
| Inventory | 21.49 Million | - | - | - | 136.17 Million | - |
| Other working capital | 56.88 Million | - | - | - | -11.8 Million | - |
| Cash at beginning of period | 859 Thousand | 783 Thousand | 36.49 Million | 859 Thousand | 1 Million | 70.25 Million |
| Cash at end of period | 1.37 Million | -49.77 Million | 783 Thousand | -53.32 Million | 858 Thousand | 859 Thousand |
| Capital Expenditure | -94.15 Million | - | - | - | -108.7 Million | - |
| Effect of forex changes on cash | - | - | - | - | 1000.00 | - |
| Net cash flow / Change in cash | 515 Thousand | -50.55 Million | -35.71 Million | -54.18 Million | -148 Thousand | -69.39 Million |
| Free Cash Flow | -118 Million | -49.77 Million | -35.71 Million | -53.32 Million | -355.83 Million | -69.39 Million |
002688
KUMPFIN
JZCP
S68
300421
MLNOV